Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005017878 | SCV005641520 | uncertain significance | Encephalopathy, progressive, early-onset, with episodic rhabdomyolysis | 2024-03-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005291133 | SCV005964092 | uncertain significance | not specified | 2025-02-13 | criteria provided, single submitter | clinical testing | The c.97C>T (p.H33Y) alteration is located in exon 2 (coding exon 2) of the TRAPPC2L gene. This alteration results from a C to T substitution at nucleotide position 97, causing the histidine (H) at amino acid position 33 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |